Literature DB >> 7734655

Arginine vasopressin-induced renal vasodilation mediated by nitric oxide.

V M Rudichenko1, W H Beierwaltes.   

Abstract

The vasoconstrictor vasopressin has been reported to induce paradoxical local vasodilation in the basilar vasculature through stimulation of the endothelium-derived relaxing factor nitric oxide (NO). We investigated the possibility that at subpressor doses, exogenous arginine vasopressin (AVP) might have a similar effect in the kidney. Ten Inactin-anesthetized rats were infused with sequential doses of AVP from 25 to 6,400 microU/min in 30-min increments. Subpressor infusion resulted in progressive renal vasodilation; renal blood flow (RBF) increased significantly going from 14 +/- 6% above basal at 200 microU/min (p < 0.02) to 27 +/- 5% (p < 0.01) at 1,600 microU/min accompanied by a 24 +/- 5% decrease in renal vascular resistance (RVR). At 6,400 microU/min, blood pressure (BP) increased 29 +/- 6 mm Hg and RVR increased. A second group of 8 rats were first given 10 mg/kg b.w. of the NO synthesis inhibitor NG-nitro-L-arginine methyl ester (L-NAME) before infusion of AVP. L-NAME increased BP 22 +/- 3 mm Hg (p < 0.001), and decreased RBF 16 +/- 3% (p < 0.005). After L-NAME, no dose of AVP had any further effect on either BP, RBF, or RVR. Continuous infusion of a single subpressor dose of 100 microU AVP resulted in a 26% increase in RBF (from 7.52 +/- 0.68 to 9.49 +/- 0.54 ml/min/g kidney weight, p < 0.001). AVP doubled urinary cyclic guanosine monophosphate excretion, a marker for renal NO synthesis, from 8.51 +/- 1.01 to 17.48 +/- 4.26 pM/min (p < 0.025).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734655     DOI: 10.1159/000159082

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  12 in total

Review 1.  A global perspective on vasoactive agents in shock.

Authors:  Djillali Annane; Lamia Ouanes-Besbes; Daniel de Backer; Bin DU; Anthony C Gordon; Glenn Hernández; Keith M Olsen; Tiffany M Osborn; Sandra Peake; James A Russell; Sergio Zanotti Cavazzoni
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

2.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial.

Authors:  Carrie A Sims; Daniel Holena; Patrick Kim; Jose Pascual; Brian Smith; Neils Martin; Mark Seamon; Adam Shiroff; Shariq Raza; Lewis Kaplan; Elena Grill; Nicole Zimmerman; Christopher Mason; Benjamin Abella; Patrick Reilly
Journal:  JAMA Surg       Date:  2019-11-01       Impact factor: 14.766

3.  Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.

Authors:  François Lauzier; Bruno Lévy; Patrice Lamarre; Olivier Lesur
Journal:  Intensive Care Med       Date:  2006-09-22       Impact factor: 17.440

Review 4.  Vasopressor therapy in critically ill patients with shock.

Authors:  James A Russell
Journal:  Intensive Care Med       Date:  2019-10-23       Impact factor: 17.440

5.  Concurrent Use of Calcium Chloride and Arginine Vasopressin Infusions in Pediatric Patients with Acute Cardiocirculatory Failure.

Authors:  Karan B Karki; Jeffrey A Towbin; Camden Harrell; James Tansey; Joseph Krebs; William Bigelow; Arun Saini; Sachin D Tadphale
Journal:  Pediatr Cardiol       Date:  2019-05-07       Impact factor: 1.655

Review 6.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

7.  Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients.

Authors:  Nameet Jerath; Helena Frndova; Brian W McCrindle; Rebecca Gurofsky; Tilman Humpl
Journal:  Intensive Care Med       Date:  2008-03-19       Impact factor: 17.440

8.  Renal vasoconstriction by vasopressin V1a receptors is modulated by nitric oxide, prostanoids, and superoxide but not the ADP ribosyl cyclase CD38.

Authors:  Nicholas G Moss; Tayler E Kopple; William J Arendshorst
Journal:  Am J Physiol Renal Physiol       Date:  2014-03-12

Review 9.  Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

Review 10.  Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.